Gilead Reiterates Faith In NASH Combination Approach After Another Trial DisappointmentBenzinga • 04/25/19
Gilead Sciences Isn't Satisfied With Only A Few NASH Deals, Presses On With MoreSeeking Alpha • 04/24/19
Gilead Has A Shot To Regain Investor Confidence With Inflammatory Disorder Drug FilgotinibSeeking Alpha • 04/03/19